Cargando…

初诊多发性骨髓瘤患者中性粒细胞与淋巴细胞比值与免疫表型、细胞遗传学的相关性及其对预后的影响

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342691/
https://www.ncbi.nlm.nih.gov/pubmed/32023739
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.12.015
_version_ 1783555571706757120
collection PubMed
description
format Online
Article
Text
id pubmed-7342691
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73426912020-07-16 初诊多发性骨髓瘤患者中性粒细胞与淋巴细胞比值与免疫表型、细胞遗传学的相关性及其对预后的影响 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2019-12 /pmc/articles/PMC7342691/ /pubmed/32023739 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.12.015 Text en 2019年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 短篇论著
初诊多发性骨髓瘤患者中性粒细胞与淋巴细胞比值与免疫表型、细胞遗传学的相关性及其对预后的影响
title 初诊多发性骨髓瘤患者中性粒细胞与淋巴细胞比值与免疫表型、细胞遗传学的相关性及其对预后的影响
title_full 初诊多发性骨髓瘤患者中性粒细胞与淋巴细胞比值与免疫表型、细胞遗传学的相关性及其对预后的影响
title_fullStr 初诊多发性骨髓瘤患者中性粒细胞与淋巴细胞比值与免疫表型、细胞遗传学的相关性及其对预后的影响
title_full_unstemmed 初诊多发性骨髓瘤患者中性粒细胞与淋巴细胞比值与免疫表型、细胞遗传学的相关性及其对预后的影响
title_short 初诊多发性骨髓瘤患者中性粒细胞与淋巴细胞比值与免疫表型、细胞遗传学的相关性及其对预后的影响
title_sort 初诊多发性骨髓瘤患者中性粒细胞与淋巴细胞比值与免疫表型、细胞遗传学的相关性及其对预后的影响
topic 短篇论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342691/
https://www.ncbi.nlm.nih.gov/pubmed/32023739
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.12.015
work_keys_str_mv AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng
AT chūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngxìnglìxìbāoyǔlínbāxìbāobǐzhíyǔmiǎnyìbiǎoxíngxìbāoyíchuánxuédexiāngguānxìngjíqíduìyùhòudeyǐngxiǎng